Nuropod offers a replacement charger for its wearable neuromodulation device, giving users who rely on structured daily sessions a dedicated, device-specific option for when an original charger wears out.
-- Nuropod, the US wellness brand of research company Parasym, has announced a replacement charger for its vagus nerve stimulation device, now available online for customers who need a backup unit.
More details on the charger, including pricing and compatibility, are available at https://nuropod.com/products/charger
The announcement reflects the scale of use behind the device, with Nuropod reporting more than 5 million user sessions completed to date. The replacement charger gives customers a device-compatible option to maintain those sessions without interruption when the original charger wears out.
Each Nuropod ships with a charger designed for long-term use. Like a phone charger, it can need replacing after frequent use. The replacement unit is priced at $25, connects through the Nuropod port, and is compatible only with the Nuropod device.
The Nuropod device itself is a non-invasive wearable. Its earpiece clips onto the tragus, the small flap of cartilage at the front of the ear, and delivers gentle, controlled electrical pulses to the auricular branch of the vagus nerve using Parasym’s proprietary AVNT™ waveform. The device is designed to support nervous system function.
Reliable charging matters because the device is designed for consistent daily use. Most people use it for around 30 minutes, once or twice a day, while working, reading, or watching television. No prescription is required, and no gel or lubricants are needed.
Parasym’s AVNT technology has been studied for its potential effects on stress, sleep, focus, and recovery, with more than 60 completed clinical studies, over 100 ongoing clinical studies underway, and over 10 years of research and development behind it. In the US, Nuropod holds an FDA Non-Significant Risk designation and is not a medical device.
Customers can order a replacement charger or learn more about the Nuropod device at https://nuropod.com/
Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-significant risk device and is not intended to diagnose, treat, cure, or prevent any disease.
Contact Info:
Name: PR Team
Email: Send Email
Organization: Nuropod by Parasym
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/
Source: PressCable
Release ID: 89208238
Should you identify any discrepancies, concerns, or inaccuracies in the content provided in this press release or require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team is committed to addressing your concerns within 8 hours by taking necessary actions to resolve identified issues diligently or guiding you through the necessary steps for removal. Our dedication lies in providing accurate and reliable information.
